The European Commission has granted conditional marketing authorization for the anti-viral drug remdesivir, making it the first drug, authorized at the EU level, which is applicable for the treatment of Covid-19. It was reported by Epravda.com with reference to the commission’s statement.
"The protection of public health is a key priority for the Commission, and therefore data on remdesivir have been evaluated in an extremely short time using a rapid review procedure, the approach used by the EMA during health emergencies in order to assess data as they become available," the statement said.
It is worth noting that 17 coronavirus vaccines are currently being tested on humans worldwide.
As we reported earlier, an international group of scientists has discovered a new mutation of coronavirus - G614. It appears to spread faster than the common form of Covid-19.
British professor Lawrence Young assumes that the new version of coronavirus is less pathogenic and patients tend to cope with symptoms easier, and it could be good news.